Literature DB >> 28369702

The unique immunological features of heparin-induced thrombocytopenia.

Phillip Staibano1, Donald M Arnold1,2, Dawn M E Bowdish3, Ishac Nazy1.   

Abstract

Heparin-induced thrombocytopenia (HIT) is a serious drug reaction that leads to a decrease in platelet count and a high risk of thrombosis. HIT patients produce pathogenic immunoglobulin G (IgG) antibodies that bind to complexes of platelet factor-4 (PF4) and heparin. HIT immune complexes crosslink Fc-receptors resulting in platelet and monocyte activation. These events lead to the release of procoagulant chemokines and tissue factor, which together create an intensely prothrombotic state. HIT represents an atypical immune response because it has features of both T cell-dependent and T cell-independent mechanisms. The disorder is characterized by newly formed anti-PF4/heparin IgG antibodies, which are characteristic of a T cell-dependent mechanism; however, re-exposure to heparin, months after HIT, does not lead to a memory response, which is consistent with a T cell-independent mechanism. In this review, we discuss the immunobiological events that can explain these features, including the role for T cell-dependent and T cell-independent mechanisms in HIT antibody generation, the immunogenic characteristics of the PF4/heparin antigen, and the concept of a temporary loss in immune regulation contributing to the onset of HIT. We also present a novel immunobiological model to explain the atypical immune response that is characteristic of HIT.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  T cells; antibodies; heparin-induced thrombocytopenia; immunology; platelet factor 4

Mesh:

Substances:

Year:  2017        PMID: 28369702     DOI: 10.1111/bjh.14603

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

2.  Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT.

Authors:  Adam J Kanack; Antonios Bayas; Gemlyn George; Mouhamed Yazan Abou-Ismail; Bandana Singh; Mindy C Kohlhagen; Noah P Splinter; Monika Christ; Markus Naumann; Karen A Moser; Kristi J Smock; Alison Grazioli; Renren Wen; Demin Wang; David L Murray; Anand Padmanabhan
Journal:  Blood       Date:  2022-07-07       Impact factor: 25.476

Review 3.  Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.

Authors:  Dennis McGonagle; Gabriele De Marco; Charles Bridgewood
Journal:  J Autoimmun       Date:  2021-05-19       Impact factor: 7.094

4.  Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin.

Authors:  B Singh; A Kanack; A Bayas; G George; M Y Abou-Ismail; M Kohlhagen; M Christ; M Naumann; K Moser; K Smock; A Grazioli; D Murray; A Padmanabhan
Journal:  medRxiv       Date:  2021-09-24

5.  The Relevance of Anti-PF4 Antibody Isotypes and Endogenous Glycosaminoglycans and their Relationship with Inflammatory Biomarkers in Pulmonary Embolism Patients.

Authors:  Bulent Kantarcioglu; Amir Darki; Fakiha Siddiqui; Debra Hoppensteadt; Joseph Lewis; Roland Krämer; Cafer Adiguzel; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

Review 6.  Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches.

Authors:  Jason B Giles; Elise C Miller; Heidi E Steiner; Jason H Karnes
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

7.  Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia.

Authors:  Sabine Sewing; Adrian B Roth; Michael Winter; Andreas Dieckmann; Cristina Bertinetti-Lapatki; Yann Tessier; Claudia McGinnis; Sylwia Huber; Erich Koller; Corinne Ploix; John C Reed; Thomas Singer; Andreas Rothfuss
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

8.  To clot or not to clot? Ad is the question-Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia.

Authors:  Maha Othman; Alexander T Baker; Elena Gupalo; Abdelrahman Elsebaie; Carly M Bliss; Matthew T Rondina; David Lillicrap; Alan L Parker
Journal:  J Thromb Haemost       Date:  2021-08-23       Impact factor: 16.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.